Tumor immune escape by the loss of homeostatic chemokine expression
- 27 November 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (48), 19055-19060
- https://doi.org/10.1073/pnas.0705673104
Abstract
The novel keratinocyte-specific chemokine CCL27 plays a critical role in the organization of skin-associated immune responses by regulating T cell homing under homeostatic and inflammatory conditions. Here we demonstrate that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)–Ras–MAPK-signaling pathways. Compared with healthy skin, CCL27 mRNA and protein expression was progressively lost in transformed keratinocytes of actinic keratoses and basal and squamous cell carcinomas. In vivo, precancerous skin lesions as well as cutaneous carcinomas showed significantly elevated levels of phosphorylated ERK compared with normal skin, suggesting the activation of EGFR–Ras signaling pathways in keratinocyte-derived malignancies. In vitro, exogenous stimulation of the EGFR–Ras signaling pathway through EGF or transfection of the dominant-active form of the Ras oncogene (H-RasV12) suppressed whereas an EGFR tyrosine kinase inhibitor increased CCL27 mRNA and protein production in keratinocytes. In mice, neutralization of CCL27 led to decreased leukocyte recruitment to cutaneous tumor sites and significantly enhanced primary tumor growth. Collectively, our data identify a mechanism of skin tumors to evade host antitumor immune responses.Keywords
This publication has 31 references indexed in Scilit:
- Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vectorCancer Gene Therapy, 2005
- Ras‐induced spreading and wound closure in human epidermal keratinocytesThe FASEB Journal, 2005
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005
- Immunotherapy and immunoselection - tumour escape as the final hurdleFEBS Letters, 2004
- Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapyBiochemical and Biophysical Research Communications, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Chemokines: agents for the immunotherapy of cancer?Nature Reviews Immunology, 2002
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- Genetic changes in skin tumor progression: Correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7Cell, 1990
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989